Lupus and scleroderma overlap features in a 28-year-old man with anti-PL-12 anti-synthetase syndrome
Lupus and scleroderma overlap features in a 28-year-old man with anti-PL-12 anti-synthetase syndrome

Jasmine Rana BA, Andrea Primiani Moy MD, Adriano Piris MD, Gideon P. Smith MD PhD
Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts

Corresponding Author: Jasmine Rana, Harvard Medical School, 6107 Ave Louis Pasteur, Boston, MA 02115, Tel: 425-533-4923, E-mail: jasmine_rana@hms.harvard.edu

Abstract
A 28-year-old man with clinically and laboratory diagnosed anti-PL-12 anti-synthetase syndrome (AS) in 2009 developed cutaneous lupus lesions, discoid lupus lesions, and sclerodactyly with finger-tip ulcers four years following his AS diagnosis. Laboratory tests including +ANA, +anti-dsDNA antibody, +anti-Smith antibody, and +anti-RNP antibody in 2014 confirmed the diagnosis of progression to an overlap syndrome including systemic lupus erythematosus. The patient now also has clinical findings (sclerodactyly, Raynaud phenomenon, finger-tip ulcers) consistent with scleroderma overlap. In each stage of his evolving connective tissue disease, cutaneous findings have been central to the recognition and monitoring of his overlap syndromes.

Keywords: anti-PL-12, anti-synthetase, lupus, scleroderma, myositis, overlap, MCTD

Introduction
Anti-synthetase syndrome (AS) is a rare syndrome in the inflammatory myopathy family that is defined by laboratory presence of an anti-aminoacyl-tRNA synthetase (anti-ARS) antibody and hallmark clinical symptoms: fevers, interstitial lung disease (~80%), mechanic’s hands (~70%), Raynaud phenomenon (~60%), and polyarthritis (~60%), [1]. Myositis may be clinically asymptomatic or mild in AS, especially when it is associated with certain antibodies, particularly anti-PL-12 and anti-PL-7 antibodies [1, 2].

Aminoacyl-tRNA synthetase is a cytoplasmic enzyme that catalyzes the binding of a specific amino acid to tRNA during protein synthesis. To date there are nine known anti-ARS antibodies and each targets a t-RNA synthetase specific for a different amino acid [3]. The anti-Jo-1 antibody is the most common anti-ARS antibody (25-30% estimated prevalence in patients with polymyositis or dermatomyositis), followed by anti-PL-7 antibody (5-10%), and anti-PL-12 antibody (<5%), [4].

We present a 28-year-old patient diagnosed with the rare anti-PL-12 subtype of AS in 2009 who subsequently developed clinical and laboratory evidence of a systemic lupus erythematosus (SLE) overlap syndrome and sclerodermatous skin findings suggestive of an additional scleroderma overlap syndrome. This case is presented to highlight a unique overlap presentation in a patient with AS and underscore the importance of monitoring patients with inflammatory myopathies for connective tissue overlap diseases that may chiefly present cutaneously, as in this patient.

Case Synopsis
In 2009, a 20-year-old man, a college student, with a history of arthralgias, dyspnea, pericarditis, recurrent fevers, periorbital edema and erythema, and poikilodermic rash on his trunk and arms was diagnosed with anti-synthetase syndrome (AS) based on his aforementioned clinical findings and +anti-PL-12 antibody. Chest CT and lung biopsy were consistent with interstitial lung disease.

A punch biopsy of the patient’s poikilodermic eruption (left upper arm) during a subsequent hospitalization showed increased dermal mucin with leukocytoclastic vasculitis and interface vacuolar changes consistent with a reactive dermatitis secondary to AS (Figure 1).
At the time of initial AS diagnosis, he had a negative ANA at 1:40 and 1:160. Anti-Ro antibody was positive at 70.5 (normal 0-19.9 OD U), anti-dsDNA antibody was negative at 1:10, and anti-RNP antibody was negative at 0.296 (normal < 0.600 OD U). CK was elevated at 3659 (normal 60-400 U/L in men). Other than his poikiloderma, he exhibited no cutaneous eruptions consistent with SLE. He had no photosensitivity, no Raynaud phenomenon, and no sclerodactyly. He was treated with prednisone and methotrexate and later transitioned to chronic prednisone and azathioprine. The patient had a complicated course following his AS diagnosis with numerous hospitalizations for acute inflammatory symptoms. Approximately 4 years after initial AS diagnosis, the patient was hospitalized for high fevers, acute respiratory distress syndrome, and pancytopenia in 2014. Serologies at this time were consistent with SLE. Negative at initial diagnosis of AS, ANA was now positive at 1:2560 with a speckled nuclear pattern and anti-dsDNA antibody was positive at 1:40. Anti-Smith antibody was positive at 235 (normal 0-19.9 OD U), anti-Ro antibody was positive at 169 (normal 0-19.9 OD U), and anti-RNP antibody was positive at 264 (normal 0-19.9 OD U). C3 and C4 were low. Lupus anticoagulant was also positive. Anti-Scl-70 antibody was negative at 3.73 (normal 0-19.9 OD U) and anti-RNA polymerase antibody was negative at < 10 (normal < 20 U). The patient’s acute symptoms resolved with solumedrol, IVIG, anakinra (IL-1 inhibitor), and rituximab. Despite his rocky course complicated by recurrent hospitalizations, the patient, now 28 years old, is currently doing well on prednisone 5 mg daily, hydroxychloroquine 400 mg daily, and rituximab 1000 mg every six months, which have helped with pulmonary, joint, and skin symptoms. His lung function has improved (FEV1/FVC = 83% predicted in 2016 vs. FEV1/FVC = 88% in 2009 around time of AS diagnosis). However, even on this treatment regimen, he developed discoid (Figure 2A) and cutaneous lupus lesions, which are being treated with intralesional and topical steroids. In the interim since his AS diagnosis, the patient also developed Raynaud phenomenon, sclerodactyly with ulcerations, and hyperkeratotic scale on his hands consistent with mechanic’s hands (Figure 2B and 2C).

The patient currently undergoes annual age-appropriate screening for cancer and PFTs. He is also screened with UA, BUN/Cr, C3, C4, dsDNA, ESR, and CRP to monitor for activity of systemic lupus, particularly renal impairment.

Case Discussion

Anti-PL-12 anti-synthetase syndrome (AS) is so rare that its exact prevalence is unknown. This is compounded by the fact that the anti-PL-12 antibody is not always assessed and lab testing was only recently made available. It is estimated that 25% of patients with polymyositis or dermatomyositis have AS, which amounts to a prevalence estimate of 3-4/100,000 worldwide [5]. AS tends to be more predominant in women than men (as high as 13:1 in some studies), [6]. Because the clinical presentation of AS can be variable and non-specific (e.g. fevers, dyspnea, arthritis), the diagnosis of AS is generally made after an establishment of myositis and when, on further testing, the patient is shown to have a positive anti-ARS antibody and presents with one or more AS symptoms [3, 6].

Since the patient’s original anti-PL-12 AS diagnosis (a case discussion about his initial presentation was previously published in 2012 [7]), we have continued to closely follow this patient in dermatology clinic. We re-present this patient now to discuss how he went on to develop autoimmune overlap features in the years following his initial AS diagnosis, including 1) systemic lupus overlap as evidenced by cutaneous...
and discoid lupus lesions with +ANA, +anti-dsDNA antibody, +anti-Smith antibody, +anti-Ro antibody, +anti-RNP antibody, and +lupus anticoagulant antibody (meets ACR criteria for systemic lupus diagnosis [8]) and 2) possible scleroderma overlap as evidenced by sclerodactyly with finger-tip ulcerations. Despite negative anti-Scl-70 antibody and anti-RNA polymerase antibody, the patient meets 2013 ACR/EULAR criteria for scleroderma diagnosis with clinical symptoms (sclerodactyly, Raynaud phenomenon, finger-tip ulcerations) alone [9].

A discussion of overlap syndromes with AS is limited by the new classification of AS a separate clinical entity (around 1990) and debate in the literature about AS being a myositis overlap syndrome in itself [10]. Generally recognized as a discrete connective tissue disease syndrome (with the presence of an anti-ARS antibody being essential to diagnosis), AS has rarely been reported to present with overlap presentations [10-13]. To the best of our knowledge, though likely underreported, this is the first case report of a patient with AS who developed serologies and cutaneous manifestations of systemic lupus erythematosus (SLE) with a concomitant scleroderma clinical overlap.

Although rare, overlap syndromes should be considered in the differential for patients with inflammatory myopathies if new clinical symptoms develop so that treatment regimens and appropriate organ-specific screening (e.g. renal impairment in systemic lupus and esophageal and pulmonary involvement in scleroderma) can be initiated. Variability in presentation has made prevalence of overlap syndromes difficult to determine [14]. In one retrospective cohort study, a non-insignificant proportion of participants with inflammatory myopathies (31 out of 220) were diagnosed with overlap syndromes (48.4% scleroderma, 29.0% SLE, 22.6% rheumatoid arthritis), [15].

Although this AS patient manifests with clear lupus and scleroderma symptoms, we are cautious to label him definitively as “AS with lupus and scleroderma overlap” in the setting of his evolving clinical picture (despite the fact that this tentative diagnosis is guiding our screening tests at present, as mentioned above). The patient’s negative anti-RNP antibody profile in 2009 that subsequently became positive in 2014 remains a diagnostic conundrum. Although anti-RNP can be positive in systemic lupus, it may also suggest that this patient may be better classified as mixed connective tissue disease (MCTD) given his overlapping features of myositis, lupus, and scleroderma and his high-titer ANA in 2009 with a nuclear speckled pattern. MCTD would be atypical as it generally presents with positive anti-RNP early in a disease course with non-specific symptoms that later evolve into a MCTD overlap [16]. The patient exhibited classic symptoms of AS early in his disease course, but this, of course, does not exclude an evolving MCTD picture. Time remains the best predictor for whether or not he will evolve into a discrete connective tissue disease [17]; diagnostic certainty may allow better prediction of his risk for

![Figure 2. New onset discoid lupus erythematosus lesions (A, arrow) and sclerodactyly in the patient's right (B) and left hand (C) evidenced by narrow tapering, shiny distal skin, associated skin atrophy, and joint contractures.](image-url)
malignancy, pulmonary disease progression, and renal failure. With regard to treatment, this patient’s pulmonary, joint, and skin manifestations acedotally improved most significantly with the initiation of rituximab. The patient was initiated on the standard rheumatoid arthritis protocol in 2014 (two doses of 1,000 mg IV rituximab separated by two weeks, every six months). In 2015, following a standard re-dosing of rituximab, the patient missed his week two infusion. On checking his B-cell depletion and clinical activity, however, it seemed well controlled and so the decision was made to try him on one dose of 1,000 mg rituximab every six months as it appeared adequate and was consistent with what has been done for some patients with rheumatoid arthritis [18, 19]. The patient remains well-controlled on the lower dosing.

Retrospective and prospective studies show that many rituximab-treated AS patients (who were often refractory to other immunosuppressive medications like our patient) had improved or stabilized lung function and exhibited improvement in lab and clinical markers of myopathy, but this needs to be further evaluated in larger controlled studies [20-22].

**Conclusion**

This case was presented for discussion of a rare subtype of anti-PL-12 AS with a focus on evolving lupus and scleroderma overlap features that have guided screening and aggressive immunosuppressive treatment. Dermatologists play a vital role in monitoring patients with connective tissue disease for overlap syndromes as they can recognize cutaneous manifestations of these diseases and ensure that appropriate work-up and screening are initiated.

**References**

